


Transcriptomic Profiling for MOA and Human Relevance Assessment

For global assessment of possible modes of action providing evidence to support a human non-relevance argument.







Performed using frozen or FFPE samples facilitating integration with sub-chronic regulatory toxicity studies.



CD-1 mouse liver left lobe section

Figures showing induction of mRNA expression for genes involved in the CAR activation at different doses of test compound 'X'



Applications:

- Accurate assessment of all Modes of Action (MOAs).
- Exclusion of Adverse Outcome Pathways (AOPs).
- Assessment of dose-response relationships.
- Identification of No Effect Level (NOEL) for key events.

Benefits:


- Can be applied in the context of regulatory sub-chronic toxicity studies.
- Links MOA to tumour relevant endpoints.
- Provides support for Human non relevance arguments.

(Left) Figures showing induction of mRNA expression for genes involved in the CAR activation signalling pathway at different doses of compound X. (A) 150 ppm (B) 300 ppm (C) 1000 ppm of test item X.

Red nodes = upregulated; green nodes = down-regulated; grey nodes = no change

Microarray Transcriptomic Profiling workflow


The following schema shows the workflow of a typical transcriptomic profiling project, following supply by client of FFPE tissue to MicroMatrices for analysis:



Microarray Transcriptomic Profiling (MTP) is only one of the services MicroMatrices use to obtain information from FFPE tissues. For more in depth information and case studies please contact Simon Plummer (contact details below), or visit our website at www.micromatrices.com

Analysis: mouse 100 ppm M

■ mouse 100 ppm M ■ mouse 250ppm M ■ mouse 750ppm M



© 2000-2016 QIAGEN. All rights reserved.